Vestibular dysfunction causes vertigo, dizziness, and imbalance, impairing daily life and leading to substantial healthcare use. Precise prevalence and economic impact remain unclear. OBJECTIVE: To estimate the one-year prevalence and direct healthcare costs of vestibular disorders in France.
No actionable change to clinical practice; this is an epidemiological cost study providing prevalence and healthcare-cost benchmarks for vestibular disease in France, not clinical guidance.
Quantifying the prevalence and direct costs of vestibular disease strengthens the case for dedicating healthcare resources and funding to vestibular diagnostics and rehabilitation.
- 01Matched case-control design using 2022–2023 French national health database (SNDS).
- 02Estimates real-world prevalence of vestibular disease in the French population.
- 03Quantifies direct healthcare costs attributable to vestibular disease vs. matched controls.
- 04Provides economic data that could inform health-policy decisions around vestibular care.
- 05Findings are France-specific and may not generalize to other healthcare systems.
The study estimates the prevalence of vestibular disease using 2022–2023 French national health data.
studysupportedDirect healthcare costs of vestibular disease can be quantified by comparing matched cases and controls in administrative health data.
studysupported- PMID
- 42163300
- DOI
- 10.1186/s12962-026-00773-6.
- Journal
- Cost Effectiveness and Resource Allocation
- Publication type
- research_article
- Evidence level
- 3
- Population
- French individuals diagnosed with vestibular disease and matched controls from the 2022–2023 national health data system (SNDS)
- Intervention
- Vestibular disease diagnosis (exposure)
- Comparator
- Matched controls without vestibular disease
Primary outcomes
Prevalence of vestibular disease in France; Direct healthcare costs attributable to vestibular disease